PLoS ONE · 2021 · 15 citations · 16 references
Life SciencesMolecular BiologyOncologyGene ExpressionGene Expression AnalysisTranscriptomicsCancer TranscriptomicsDifferential Gene Expression AnalysisExpression Signature DiscoveryGene Expression ProfilingMutation AnalysisTranscriptomic ProfilingAcute LeukemiasAcute Myeloid Leukemia TreatmentDifferential Expression EnrichmentDifferential Transcript ExpressionFlt3 InhibitionFlt3 InhibitorsHierarchical ClusteringWilcoxon Signed-rank Test
BACKGROUND: FLT3 mutation is present in 25-30% of all acute myeloid leukemias (AML), and it is associated with adverse outcome. FLT3 inhibitors have shown improved survival results in AML both as upfront treatment and in relapsed/refractory disease. Curiously, a variable proportion of wild-type FLT3 patients also responded to these drugs. METHODS: We analyzed 6 different transcriptomic datasets of AML cases. Differential expression between mutated and wild-type FLT3 AMLs was performed with the Wilcoxon-rank sum test. Hierarchical clustering was used to identify FLT3-mutation like AMLs. Finally, enrichment in recurrent mutations was performed with the Fisher's test. RESULTS: A FLT3 mutation-like gene expression pattern was identified among wild-type FLT3 AMLs. This pattern was highly enriched in NPM1 and DNMT3A mutants, and particularly in combined NPM1/DNMT3A mutants. CONCLUSIONS: We identified a FLT3 mutation-like gene expression pattern in AML which was highly enriched in NPM1 and DNMT3A mutations. Future analysis about the predictive role of this biomarker among wild-type FLT3 patients treated with FLT3 inhibitors is envisaged.
16
Genomic Classification and Prognosis in Acute Myeloid Leukemia
Elli Papaemmanuil, Moritz Gerstung, Lars Bullinger et al. · New England Journal of Medicine · 2016 · 4.4K citations · Full text
Life Sciences, Genetics, Oncology +14
WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs
Yuxing Liao, Jing Wang, Eric J. Jaehnig et al. · Nucleic Acids Research · 2019 · 3.5K citations · Full text